Does metabolite matter? Defining target itraconazole and hydroxy‐itraconazole serum concentrations for blastomycosis
Mycoses · 2023
DOI: 10.1111/myc.13565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2023. Verfasst von Danielle Firkus und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Itraconazole, Blastomycosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Background
Itraconazole is the recommended first‐line treatment for mild‐to‐moderate blastomycosis and consolidation treatment of moderate‐to‐severe disease. Itraconazole is metabolised into three metabolites, including an active metabolite hydroxy‐itraconazole. Literature provides little evidence indicating whether therapeutic drug monitoring targets should be based on itraconazole parent compound alone or a sum of itraconazole and hydroxy‐itraconazole serum concentrations.
Objectives
This study aims to compare clinical outcomes and adverse drug events (ADEs) of combined itraconazole and hydroxy‐itraconazole concentrations versus itraconazole parent compound alone in patients with blastomycosis. Patients/Methods This study was a retrospective cohort review of patients ≥18 years with probable or proven Blastomyces infection who received itraconazole with at least one documented serum itraconazole concentration. The primary outcome was rate of partial or complete treatment response across three patient groups: (1) Itraconazole parent compound >1.0 mcg/ml (parent), (2) parent compound 1.0 mcg/ml (combined) and (3) failure to achieve a combined or parent concentration >1.0 mcg/ml (subtherapeutic) for >75% of the duration of itraconazole therapy.
Results
A total of 80 patients were included (parent = 32, combined = 36, subtherapeutic = 12). No statistically significant difference was observed for rate of partial or complete treatment response (97% parent vs 94% combined, p = .99). Significantly higher mortality due to blastomycosis was observed in patients in the subtherapeutic group (0% parent vs 3% combined vs 25% subtherapeutic, p = .01).
Conclusions
This study supports an itraconazole therapeutic target combining itraconazole and hydroxy‐itraconazole >1.0 mcg/ml for blastomycosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Danielle Firkus, Paul J Jannetto, Kristin Mara, Paschalis Vergidis, Christina G Rivera, Ryan W Stevens
Zitieren
APA
Firkus, D., Abu Saleh, O. M., Enzler, M. J., Jannetto, P. J., Mara, K., Vergidis, P., Rivera, C. G., & Stevens, R. W. (2023). Does metabolite matter? Defining target itraconazole and hydroxy‐itraconazole serum concentrations for blastomycosis. Mycoses. https://doi.org/10.1111/myc.13565
Vancouver
Firkus D, Abu Saleh OM, Enzler MJ, Jannetto PJ, Mara K, Vergidis P, et al. Does metabolite matter? Defining target itraconazole and hydroxy‐itraconazole serum concentrations for blastomycosis. Mycoses. 2023. doi:10.1111/myc.13565
BibTeX
@article{Firkus2023,
author = {Firkus, Danielle and Abu Saleh, Omar M and Enzler, Mark J and Jannetto, Paul J and Mara, Kristin and Vergidis, Paschalis and Rivera, Christina G and Stevens, Ryan W},
title = {Does metabolite matter? Defining target itraconazole and hydroxy‐itraconazole serum concentrations for blastomycosis},
journal = {Mycoses},
year = {2023},
doi = {10.1111/myc.13565}
}
EUVIMED